Related Experiment Videos
What's new in fungal infection in leukemic patients
1Department of Medical Specialties, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
Abstract:
Fungal infections have become an important cause of mortality in patients with hematological malignancies. In recent years, fungi such as Candida tropicalis, Aspergillus spp, Fusarium spp and Trichosporon spp have emerged as important pathogens. Amphotericin B remains the antifungal agent with the broadest spectrum of activity, although some of the newer pathogens may be resistant. The administration of this drug in lipid vehicles reduces the toxicities, permitting the administration of higher doses that may be more effective. The new agents, fluconazole and itraconazole, have activity against some fungal pathogens, although their role in therapy has not been fully determined. Fluconazole has been shown to be effective for prophylaxis of Candida infections.
Insights
Fungal infections are a major cause of death in hematological cancer patients. Lipid formulations of Amphotericin B and newer antifungals like fluconazole offer treatment options, with fluconazole showing promise for Candida infection prophylaxis.
Area of Science:
- Medical Mycology
- Hematology
- Infectious Diseases
Background:
- Fungal infections pose a significant mortality risk for patients with hematological malignancies.
- Emerging fungal pathogens like Candida tropicalis, Aspergillus spp, Fusarium spp, and Trichosporon spp are increasingly recognized.
- Traditional antifungals face challenges with resistance and toxicity.
Purpose of the Study:
- To review the current landscape of fungal infections in hematological malignancy patients.
- To discuss the role of established and novel antifungal agents in managing these infections.
- To highlight strategies for improving antifungal therapy efficacy and safety.
Main Methods:
- Literature review of recent studies on fungal infections in hematological malignancies.
- Analysis of antifungal drug spectra of activity, including Amphotericin B, fluconazole, and itraconazole.
- Evaluation of drug delivery systems, such as lipid formulations for Amphotericin B.
Main Results:
- Amphotericin B, despite potential resistance in newer pathogens, remains a broad-spectrum antifungal.
- Lipid formulations of Amphotericin B enhance safety and allow for higher, potentially more effective doses.
- Fluconazole and itraconazole show activity against certain fungi, with fluconazole demonstrating efficacy in Candida infection prophylaxis.
Conclusions:
- Fungal infections remain a critical concern in immunocompromised hematology patients.
- Optimized delivery of broad-spectrum agents like Amphotericin B is crucial.
- Newer azoles, particularly fluconazole for prophylaxis, represent important therapeutic advancements.